Q-omics provides the consensus-scored ALDH1L1-AS1 profile across patient tissues and cancer cell-line models. ALDH1L1-AS1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ALDH1L1-AS1 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, ALDH1L1-AS1 RNA expression shows 10,023 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight THCA, LIHC, and SARC as cancer lineages where ALDH1L1-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALDH1L1-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALDH1L1-AS1 survival associations across molecular data types. ALDH1L1-AS1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALDH1L1-AS1 RNA expression–survival associations across cancer types. High ALDH1L1-AS1 expression shows unfavorable associations in THCA, CHOL, READ, LUSC, ACC and COAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for ALDH1L1-AS1 RNA expression.
This table summarizes ALDH1L1-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ALDH1L1-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALDH1L1-AS1 shows lower tumor expression in BRCA, CHOL, THCA and PRAD and higher tumor expression in LIHC and KIRC. The LIHC box plot shows higher ALDH1L1-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.348, t-test p = .007).
This table shows molecular features associated with ALDH1L1-AS1 in patient tissues and cancer cell lines. In patient samples, ALDH1L1-AS1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
